INCY News and Press, Incyte Corporation From 07/31/20

- First FDA approval of a second-line treatment for adult patients with relapsed or refractory DLBCL, helping fill a high unmet medical need - FDA granted Monjuvi Fast Track, Breakthrough Therapy and Priority Review designations - MorphoSys and Incyte will co-commercialize Monju...

Investment Thesis On December 29, 2019, I published an article, " Incyte Corporation: Wait And Watch ", in which I wrote, Incyte ( INCY ) provides the potential for very high returns, based on analysts' EPS estimates and a high P/E multiple. There are also significant downside risks if EP...

INCY has hit a ceiling at $110. Look for when the stock closes above this resistance level. Incyte Corp. ( INCY ) has been trending higher since hitting its 52-week low on March 23rd.  Yet, now the rally has stalled and a key resistance level has formed. INCY focuses on the ...

Incyte (NASDAQ: INCY ) announces positive results from a Phase 3 clinical trial, REACH3 , evaluating Jakafi (ruxolitinib) in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GvHD). The study met the primary endpoint demonstratin...

- Jakafi ® demonstrated superior overall response rate in patients with steroid-refractory chronic graft-versus-host disease (GVHD) at Week 24 compared to best available therapy - The study also met both key secondary endpoints, significantly improving patient-reported symptoms a...

A recent study from the National Comprehensive Cancer Center (NCCN) delivered a shocking indictment of the oncology field as a whole, stating that almost 70% of women diagnosed with triple-negative breast cancer (TNBC) do not receive care for their disease that is in accordance with guideli...

Approach I have dedicated dozens, if not hundreds, of hours to backtesting various concepts based on fundamental data of companies and technical analysis of price action and volume. Despite such high volatility on the market and so many moving parts, I still pay attention to the suggestions ...

Shares of Incyte (NASDAQ: INCY) rose more than 19% in the first six months of the year, according to data provided by S&P Global Market Intelligence . That easily bested the 4% decline of the S&P 500 in that span. After struggling to commercialize pipeline assets in recent years ...

- The approval of Tabrecta in Japan follows U.S. FDA approval earlier this year - Tabrecta is the third Incyte-discovered molecule to be approved by the MHLW - Novartis has exclusive worldwide development and commercialization rights to Tabrecta Incyte (Nasdaq: INCY) today an...

Oncolytics Biotech (NASDAQ: ONCY ) announces a new investigator-sponsored triple-negative breast cancer (TNBC) study to be managed by Rutgers Cancer Institute of New Jersey. More news on: Oncolytics Biotech Inc., Incyte Corporation, Healthcare stocks news, Read more ...